Ilya Pharma announces positive results from Phase I trial of lead candidate ILP100 and rapid move to Phase II

Success also de-risks the use of ILP-drug candidates in other medical indications, including the company’s inflammatory bowel disease program.

Ilya Pharma extends research collaboration with Uppsala University

Meet Stefan Roos co-founder and innovator for multiple patents of commercial strains of lactic acid bacteria

Ilya Pharma will present at the Swiss Nordic Bio 10-11 February 2021

Latest clinical developments and next raise to be presented at EIC Investor Day 2.0 17-18 December

Ilya Pharma presented at the Redeye unlisted event December 2

FDA open to new endpoints for patients with difficult wounds

FDA opened for 5 new endpoints in Nov 2020 (vs. only 1 until then) following thorough work by FDA’s Inter-center Wound Healing Work group and industry Wound Experts/FDA Clinical Endpoints Project.

Meet Ingemar Kihlstörm - facilitating the next stage of growth

Financing innovations in pharmaceutical development – facilitating the next stage of growth

Operational Report Q3 2020

Meet Margareth Jorvid leading innovations to products